Discontinued — last reported Q2 '23
Year-over-year, this metric grew by 100.0%, from -$21.00M to $0.00. Over 2 years (FY 2021 to FY 2023), Acquisitions shows a downward trend with a -100.0% CAGR.
High spending indicates an aggressive growth strategy, while low spending may indicate a focus on organic growth or debt reduction.
This represents the net cash outflow for the purchase of other businesses or strategic assets, adjusted for any cash acq...
Highly variable; pharmaceutical companies frequently use M&A to offset patent cliffs and expand therapeutic portfolios.
acquisitions| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $104.00M | $225.00M | $415.00M | $35.00M | $0.00 | $1.62B | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $8.00M | -$21.00M | $0.00 | $0.00 |
| QoQ Change | — | +116.3% | +84.4% | -91.6% | -100.0% | — | -100.0% | — | — | — | — | — | -362.5% | +100.0% | — |
| YoY Change | — | — | — | — | -100.0% | +620.0% | -100.0% | -100.0% | — | -100.0% | — | — | — | -100.0% | +100.0% |